All Updates

All Updates

icon
Filter
M&A
Lantern Pharma forms new subsidiary, Starlight Therapeutics, to focus on CNS and brain cancer treatments
AI Drug Discovery
Mar 6, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Mar 6, 2023

Lantern Pharma forms new subsidiary, Starlight Therapeutics, to focus on CNS and brain cancer treatments

M&A

  • Texas-based AI biopharmaceutical company Lantern Pharma has launched a new wholly-owned subsidiary called “Starlight Therapeutics,” dedicated to developing novel treatments focused on the central nervous system (CNS) and brain cancers. 

  • Following the launch of Starlight, Lantern’s small molecule candidate, LP-184, will be referred to as STAR-001 for CNS indications while Lantern will continue to evaluate and advance LP-184 for other non-CNS indications. 

  • The formation of Starlight is expected to increase the probability of securing partnerships with other biotech and biopharma companies that focus on CNS cancers. Starlight will also be able to leverage Lantern’s AI-powered platform, RADR, to accelerate the discovery of novel therapeutics. 

  • Lantern expects to initiate Phase Ia clinical trials of STAR-001 for a number of cancer indications, including glioblastoma (GBM), brain metastases, and several rare pediatric CNS cancers from mid-2023. Following this, Starlight will be solely responsible for conducting further clinical trials for STAR-001.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.